VITAN-BIOTECH LLC

Aurora, CO · Biotech · Private

Nanobodies against G-protein coupled receptors (GPCRs) generated via cell-free membrane protein synthesis and phage-display technology

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · vitan-biotech.com

Sector: Biotech
Headquarters: Aurora, CO
Total capital: $2.5M

Federal grants: $1.9M; 9 awards · 2017–2024; Rank in peer group#120 of 502
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $550K; 3 awards · Health and Human S; Rank in Biotech#226 of 4373
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Jul 2024Federal grantHealth and Human S · Phase I · Field-Deployable, low-Cost Point-of-Need urine test strips for mobile quantification of SUD medication drugs and their metabolites$293K
Sep 2023Federal grantHealth and Human S · Phase I · Developing an integrated pipeline for routine generation of orthogonal GPCR-targeting nanobodies$219K
Sep 2023Federal grantHealth and Human S · Phase I · Developing an integrated pipeline for routine generation of orthogonal GPCR-targeting nanobodies$219K
Aug 2020Federal grantHealth and Human S · Phase I · Plasmonic Glycan Arrays for Highly Sensitive Detection of Glycan-binding Proteins$223K
Jul 2020Federal grantHealth and Human S · Phase I · Plasmonic Glycan Arrays for Highly Sensitive Detection of Glycan-binding Proteins$223K
Apr 2020Federal grantHealth and Human S · Phase I · Development of safe and effective immunotherapeutics for treatment of opioid abuse and overdose$225K
Feb 2020Federal grantHealth and Human S · Phase I · Development of safe and effective immunotherapeutics for treatment of opioid abuse and overdose$225K

Show 5 earlier federal awards

Jul 2019Federal grantHealth and Human S · Phase I · Developing high-affinity nanobodies to tumor-associated glycan antigens$150K
Sep 2017Federal contractHealth and Human S · Igf::ot::igf Single Domain Antibodies For Detection And Imaging Of Modified Rna Nucleosides$250K
Feb 2017Federal grantHealth and Human S · Phase I · High sensitive and specific, Point-of-use lateral flow strip for on-site test of cannabis intoxication$132K
May 2016Federal contractHealth and Human S · Igf::ot::igf Research And Development Under SBIR$150K
Sep 2015Federal contractHealth and Human S · Igf::ct::igf For Critical Functions$150K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

Federal grants#120 · top 24%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

GUILD ASSOCIATES INCShares a founder: XICHUN ZHOU
TERA-PRINT LLCSimilar federal contract value in Biotech · $569K in contracts
ABTERRA BIOSCIENCES, INC.Similar federal contract value in Biotech · $556K in contracts
ALLELE BIOTECHNOLOGY AND PHARMACEUTICALSSimilar federal contract value in Biotech · $550K in contracts
Oleolive, Inc.Similar federal contract value in Biotech · $550K in contracts
FERROLOGIX INCSimilar federal contract value in Biotech · $548K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.